RNS Number : 4483X
Nanosynth Group PLC
30 August 2022
 

 

30 August 2022 

nanosynth group plc

("nanosynth", the "Company" or the "Group")

 

Joint Development Agreement in Cosmetics Market

 

nanosynth, the AIM quoted company specialising in the synthesis and application of nanoparticles to create new and improve existing products, is pleased to announce they have entered into a joint development agreement with a global wellness company for their first project in the cosmetics market.

It is anticipated that the development programme will run for 12 months and involve two major work packages. Both companies will retain their own intellectual property but will jointly work to develop a revolutionary product for the market. On successful completion and subject to results, it is the intention of both companies to enter into an exclusive commercial agreement for the supply of nanoparticles for this cosmetics market.

Mark Duffin, Chief Executive of nanosynth, commented: "We are delighted to secure the first project in our R&D programme which is testimony to our leadership in the field of Nano technology. Our client's confidentiality and competitive advantage remain our priority during this development phase and we look forward to becoming their exclusive partners in the future."

 




The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ('MAR') which has been incorporated into UK law by the European Union (Withdrawal) Act 2018.  Upon the publication of this announcement via Regulatory Information Service ('RIS'), this inside is now considered to be in the public domain.

 

 

 

ENQUIRIES:

 

nanosynth group plc

via IFC Advisory

Mark Duffin (Chief Executive Officer)

 


SP Angel Corporate Finance LLP 

+44 20 3470 0470

Nominated Adviser and Broker


Stuart Gledhill


Caroline Rowe

 


IFC Advisory Ltd

+44 20 3934 6630

Graham Herring


Zach Cohen


 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRBRGDIUSDDGDL